---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-26-000015"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-08-06T20:06:04+00:00"
generated_at: "2026-08-06T20:08:49.856114+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q2 revenue up 20% to $990M; GAAP EPS $0.23 vs $1.23; raises VOXZOGO guidance

## Summary
- Total revenues $990M (+20% YoY); GAAP net income $45M ($0.23 diluted EPS) vs $241M ($1.23) in Q2 2025.
- Non-GAAP income $236M ($1.20 diluted EPS) vs $282M ($1.44) in prior year, down 16%.
- VOXZOGO revenue $253M (+14% YoY); full-year guidance raised to at least $1B.
- Amicus acquisition closed April 27; cost synergies of ~$280M GAAP / ~$220M non-GAAP expected fully realized by 2028.
- Pipeline: sNDA submitted for VOXZOGO in hypochondroplasia; BMN 401 discontinued after Phase 3 miss.

## SEC filing metadata
- accession: 0001048477-26-000015
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-08-06T20:06:04+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/0001048477-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/bmrn-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-26-000015
- JSON: https://secwatch.observer/filing/0001048477-26-000015.json
- Plain text: https://secwatch.observer/filing/0001048477-26-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.